An Act Concerning Drugs Prescribed To Treat Attention-deficit/hyperactivity Disorder.
Summary
SB 150 would amend Connecticut’s pharmacy laws to require a pharmacist to dispense a drug prescribed to treat attention-deficit/hyperactivity disorder, so long as the patient presents a valid prescription and also provides a quantitative electroencephalogram (qEEG) brain map produced for that patient. The bill is framed as a clarification of when dispensing is mandatory, but in practical terms it adds a new condition tied to a specific type of brain imaging or mapping document.
The proposal appears to target ADHD medications, which are often controlled substances and subject to heightened dispensing scrutiny. By making a qEEG brain map part of the dispensing criteria, the bill would create a new statutory requirement affecting pharmacists, prescribers, and patients seeking ADHD treatment, and would likely interact with existing rules governing prescription validity and pharmacist discretion under chapter 400j of the general statutes.
Impact
If enacted, the bill would amend chapter 400j of the Connecticut General Statutes to impose a new mandatory-dispensing rule for ADHD medications when a patient provides both a valid prescription and a qEEG brain map. This would affect pharmacy practice by narrowing the circumstances under which a pharmacist may refuse to dispense such medication, while also potentially creating a new documentation requirement for patients and prescribers. The bill could also raise questions about how the new requirement fits with existing controlled-substance, medical-necessity, and professional-judgment standards.
Sentiment
There is no recorded committee transcript or vote history available for this bill, so there is no direct evidence of support or opposition from debate or roll call. Based on the bill text alone, the measure appears to be presented as a consumer-access or treatment-access proposal, but the absence of discussion makes the overall sentiment unclear. Any public reaction would likely depend on views about the medical validity and practicality of requiring a qEEG brain map for ADHD medication dispensing.
Contention
The main point of contention is likely to be the requirement that a patient provide a quantitative electroencephalogram brain map as a condition for dispensing ADHD medication. Supporters may view this as a way to further specify or validate treatment decisions, while opponents may argue it is medically unnecessary, burdensome, expensive, or outside standard pharmacy practice. Pharmacists and medical professionals could also dispute whether the bill improperly limits professional discretion or creates an unusual prerequisite for access to prescribed medication.